Class / Patent application number | Description | Number of patent applications / Date published |
514130600 | Fibrin or derivative affecting or utilizing | 21 |
20100331254 | PULVERIZED FIBRIN CLOTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - Provided is a pulverized fibrin clot and a pharmaceutical composition including a pulverized fibrin clot. The pharmaceutical composition may contain the pulverized fibrin clot suspended in a gel such as cross-linked hyaluronic acid. The pharmaceutical composition may be in a form suitable for injection and may be used, for example, in the treatment of connective tissue, such as skin connective tissue. Also provided is a method for preparing a pulverized fibrin clot as well as a method for treating connective tissue using the pharmaceutical composition. | 12-30-2010 |
20110009324 | Stable Therapeutic Proteins - The invention relates to storable medicaments produced from pharmaceutical active ingredient preparations which are virus safe. Said medicaments contain at least one intact therapeutic protein obtained from plasma or by means of genetic engineering, as an active pharmaceutical substance. Said active ingredient preparations contain active enzymes, especially proteases, which are either free or bound to the substrates thereof and act against the therapeutic protein(s) present. | 01-13-2011 |
20110028396 | MEDICAL COMPOSITION - It is an object of the present invention to attach a biopolymer composition to a synthetic polymer substrate without the use of a toxic adhesive. The present invention provides a medical composition, wherein a synthetic polymer substrate and a composition mainly composed of a biopolymer directly adhere to each other due to dissolution of the surfaces thereof. | 02-03-2011 |
20110034388 | COLLAGEN AND FIBRIN MICROTHREADS IN A DISCRETE THREAD MODEL OF IN VITRO ACL SCAFFOLD REGENERATION - Compositions that include fibrin microthreads are provided. The compositions can include one or more therapeutic agents including cytokines and interleukins, extracellular matrix proteins and/or biologically active fragments thereof (e.g., RGD-containing peptides), hormones, vitamins, nucleic acids, chemotherapeutics, antibiotics, and cells. Also provided are methods of making compositions that include fibrin microthreads. Also provided are methods for using the compositions to repair or ameliorate damaged or defective organs or tissues. | 02-10-2011 |
20110071083 | Modification of the properties of a fibrin matrix with respect to growth and ingrowth of cells - A method for modifying the properties of a fibrin matrix relative to growth and ingrowth of cells, wherein for forming the fibrin matrix a fibrinogen is used consisting of a selected fibrinogen variant or a fibrinogen enriched or depleted in a selected fibrinogen variant. In particular, the use of high-molecular weight (HMW) fibrinogen leads to a fibrin having accelerated angiogenesis properties, while the use of low-molecular weight (LMW and/or LMW′) fibrinogen leads to fibrin having decelerated angiogenesis properties. The use of HMW fibrinogen when setting up angiogenesis tests results in that the tests require less time. Fibrin sealants on the basis of HMW fibrinogen can be used for burns, to promote wound healing or to inhibit scar tissue. Fibrin sealants on the basis of LMW or LMW′ fibrinogen are useful to inhibit adhesions and tumor growth, for instance after surgical operations. | 03-24-2011 |
20110319331 | NOVEL USES OF FIBRINOGEN - The invention relates to the use of fibrinogen for manufacturing a medicinal product for use in the prevention or treatment of severe acute haemorrhage, the medicinal product being intended for administration in an amount equal to at least 4.5 g of fibrinogen in a single dose. | 12-29-2011 |
20120208758 | COMPOSITION FOR THE ATTACHMENT OF IMPLANTS TO COLLAGEN OR OTHER COMPONENTS OF BIOLOGICAL TISSUE - The present invention relates to a novel composition comprising an implant, scaffold or construct bound to a biological or chemical moiety. The bound moiety has the ability to bind to a component of the extracellular matrix of biological tissue, allowing the implant to be bound to the biological tissue in a short period of time after implantation. The invention also relates to the use and manufacture of this novel composition, as well as a novel use for the protein CNA. | 08-16-2012 |
20120289467 | Compositions and Methods Utilizing Fibrin Beta Chain Fragments - A composition including a peptide sequence of the formula βX1-X2, the peptide sequence corresponding to an amino acid sequence of a fibrin beta chain fragment of a Bbeta chain of fibrinogen, wherein X1 represents an N-terminal end of the peptide sequence, and X2 represents a C-terminal end of the peptide sequence, wherein the peptide sequence includes additional amino acids between X1 and X2, wherein the peptide sequence may contain a non-naturally occurring amino acid residue, wherein the peptide sequence is other than a wild-type β15-42 monomer sequence per se, and wherein the peptide sequence is other than (β15-66) | 11-15-2012 |
20130029913 | ARTIFICIAL PLATELETS - Therapeutic agents suitable for use as artificial platelets are described. The agents comprise a fibrinogen binding precursor bound to an insoluble carrier, wherein the fibrinogen binding precursor can be converted by a wound site specific agent, such as thrombin, to a fibrinogen binding component bound to the carrier. The fibrinogen binding component has increased ability to bind fibrinogen compared to the fibrinogen binding precursor. The agents may be used to treat patients with deficiencies in their own platelets, such as hereditary or acquired defects of platelet numbers (thrombocytopenia) or function (thrombasthenia). | 01-31-2013 |
20130267466 | Treatment Of Bleeding With Low Half-Life Fibrinogen - The invention provides low-half life fibrinogen as a result of recombinant expression or enzymatic and chemical removal. The low-half life fibrinogen is useful in treating or effecting prophylaxis of bleeding particularly in situations of an acute nature in which a high initial dose and rapid decline to normal or below normal levels is desirable. | 10-10-2013 |
20130267467 | SERINE PROTEASE INHIBITORS - The invention provides methods of making and using compounds of the formula shown, which are inhibitors of human plasmin and plasma kallikrein. (Formula I) The compounds are useful for the prevention of blood loss, and as components of fibrin adhesives. | 10-10-2013 |
20130338073 | DURABLE HAEMOSTATIC SCAFFOLD - A haemostatic and adhesive durable scaffold useful for promoting wound healing is provided. A scaffold made of fibrinogen and chitosan is produced by electrospinning techniques, resulting in a material with enhanced endurance, applicable in various medical purposes including surgery, tissue regeneration, burns, injuries, etc. Scaffold is produced in the absence of biocatalysts, in particular thrombin. | 12-19-2013 |
20140031293 | THERAPEUTIC AGENTS WITH IMPROVED FIBRINOGEN BINDING - Therapeutic agents with improved fibrinogen binding properties are described. The agents are suitable for use as artificial platelets, or for formation of biogels. Methods and intermediates for producing the agents, cross-linking agents for use in the methods, and biogels formed from, or comprising the agents, are also described. | 01-30-2014 |
20140187492 | Single Component Fibrin Hemostat - ClotGel is a single-component hemostatic agent designed for use as an adjunct or primary treatment in moderate intraoperative hemorrhage and in trauma. It can be applied topically to the wound either on the skin in a laparatomy or as non-invasive manner in surgical procedures. Its crosslinking technology generates an adhesive stable fibrin clot using a single component (fibrin II) required for hemostasis. The agent is a mixture of lyophilized polymerized fibrin II and fibrin II monomer which is polymerized and stabilized when in contact with the blood. The attachment properties of the gel, as well as the rapid formation of a fibrin clot, ensures that a strong stable fibrin clot is formed within 1 minute of application. | 07-03-2014 |
20150025009 | COLLAGEN AND FIBRIN MICROTHREADS IN A DISCRETE THREAD MODEL OF IN VITRO ACL SCAFFOLD REGENERATION - Compositions that include fibrin microthreads are provided. The compositions can include one or more therapeutic agents including cytokines and interleukins, extracellular matrix proteins and/or biologically active fragments thereof (e.g., RGD-containing peptides), hormones, vitamins, nucleic acids, chemotherapeutics, antibiotics, and cells. Also provided are methods of making compositions that include fibrin microthreads. Also provided are methods for using the compositions to repair or ameliorate damaged or defective organs or tissues. | 01-22-2015 |
20150105319 | DURABLE HAEMOSTATIC SCAFFOLD - A method for preparing a haemostatic and adhesive durable scaffold useful for promoting wound healing, and the scaffold so prepared, are provided. The scaffold made of fibrinogen and chitosan is produced by electrospinning techniques, resulting in a material with enhanced endurance, applicable in various medical purposes including surgery, tissue regeneration, burns, injuries, and the like. The scaffold is produced in the absence of biocatalysts, in particular thrombin. | 04-16-2015 |
20150366947 | A Method of Purifying Therapeutic Proteins - The present invention relates generally to a method of reducing the level of at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) in a solution comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and von Willebrand factor (VWF), the method comprising: (i) passing a feedstock comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF through a hydrophobic charge-induction chromatographic resin under conditions selected such that at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) present in the feedstock is bound to the resin; and (ii) recovering a solution comprising the at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF which passes through the resin, wherein the concentration of the at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) in the solution is reduced by at least 50% compared to the feedstock. Also provided are solutions and pharmaceutical formulations comprising the fibrinogen and/or Factor VIII and/or VWF recovered by such methods, and uses thereof. | 12-24-2015 |
20160095954 | FIBRIN MICROTHREADS - Compositions that include fibrin microthreads are provided. The compositions can include one or more therapeutic agents including cytokines and interleukins, extracellular matrix proteins and/or biologically active fragments thereof (e.g., RGD-containing peptides), hormones, vitamins, nucleic acids, chemotherapeutics, antibiotics, and cells. Also provided are methods of making compositions that include fibrin microthreads. Also provided are methods for using the compositions to repair or ameliorate damaged or defective organs or tissues. | 04-07-2016 |
20160106815 | TREATMENT OF BLEEDING WITH LOW HALF-LIFE FIBRINOGEN - The invention provides low-half life fibrinogen as a result of recombinant expression or enzymatic and chemical removal. The low-half life fibrinogen is useful in treating or effecting prophylaxis of bleeding particularly in situations of an acute nature in which a high initial dose and rapid decline to normal or below normal levels is desirable. | 04-21-2016 |
20160121017 | SINGLE SOLUTION of Gel-LIKE FIBRIN HEMOSTAT - The present invention trademarked ClotGel© is a fibrin II-based hemostat made of two components that are mixed into a single syringe to be delivered as an adjunct or primary treatment in moderate intraoperative hemorrhage and in trauma. It can be applied topically to the wound either on the skin in a laparatomy or as non-invasive manner in surgical procedures. Its cross-linking technology generates an adhesive stable fibrin clot required for hemostasis. The agent consists of a cross-linked gelatin that is homogenized in a solution of fibrin monomer in acetic acid, which is reconstituted before use from a lyophilized fibrin monomer. When both components are mixed into a syringe they produce a viscous gel-like composition that is polymerized and stabilized when in contact with blood. The attachment properties of the composition, as well as the rapid formation of a fibrin clot, ensures that a strong stable blood clot is formed over a bleeding wound within 2 minutes of application. | 05-05-2016 |
20160158323 | Fibrinogen Preparations Enriched in Fibrinogen With An Extended Alpha Chain - The present invention relates to fibrinogen preparations enriched in α-extended fibrinogen. Compositions comprising such preparations show improved clotting properties compared to preparations based on HMW Fib which typically contain no or only low amounts of α-extended fibrinogen. In particular, clot formation time and the clot strength of a clot made by α-extended fibrinogen are improved. In addition, plasmin-mediated degradation of α-extended fibrinogen is reduced as compared to plasma derived fibrinogen. | 06-09-2016 |